Free Account Opening + AMC Free Demat
Loading...

Aarti Drugs Buyback 2024 vs Nucleus Software Buyback 2024

Comparision between Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024.

Buyback Details

Aarti Drugs Buyback 2024 is a Tender Offer buyback proposed to list at BSE, NSE while Nucleus Software Buyback 2024 is a Tender Offer proposed to list at BSE, NSE.

  Aarti Drugs Ltd. Nucleus Software Exports Ltd.
Logo Aarti Drugs Buyback 2024 Logo Nucleus Software Buyback 2024 Logo
Type of Buyback Tender Offer Tender Offer
Listing At BSE, NSE BSE, NSE
Face Value ₹10 per share ₹10 per share
Buyback Price ₹900 per share ₹1615 per share
Issue Size 6,65,000 shares 4,48,018 shares
Issue Size (Amount) ₹59.85 Crores ₹72.35 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders9 Equity Shares out of every 706 Fully paid-up Equity Shares held on the Record Date.99,750
General Category for all other Eligible Shareholders5 Equity Shares out of every 744 Fully paid-up Equity Shares held on the Record Date.5,65,250
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders3 Equity Shares out of every 50 Fully paid-up Equity Shares held on the Record Date.67,203
General Category for all other Eligible Shareholders8 Equity Shares out of every 497 Fully paid-up Equity Shares held on the Record Date.3,80,815
Registrar Link Intime India Private Ltd Kfin Technologies Limited
Lead Managers Inga Ventures Pvt Ltd Corporate Professionals Capital Private Ltd
Necessity of the buyback

The Company is proposing the Buyback to service the equity more efficiently. Additionally, the Company’s management strives to increase equity shareholder's value and the Buyback would result in amongst other things:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares;
  2. The Buyback is generally expected to improve return on equity through the distribution of cash and improve earnings per share by a reduction in the equity base, thereby leading to a long-term increase in shareholders’ value;
  3. The Buyback gives an option to the shareholders holding Equity Shares of the Company, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding, post the Buyback offer, without additional investment; and
  4. The Buyback, which is being implemented through the tender offer as prescribed under the Buyback Regulations, would involve a minimum reservation of 15% for Small Shareholders and allocation of a higher number of shares as per their entitlement or 15% of the number of shares to be bought back, reserved for the Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would be classified as Small Shareholders.

The current Buyback is a capital allocation decision taken to seek a fairer valuation of the Company's stock while improving the Company's Return on Equity and increasing shareholder value in the longer term. The Buyback is being undertaken by the Company after taking into account the strategic and operational cash needs of the Company in the medium term and thereby returning surplus funds to the equity shareholders, which are over and above its ordinary capital requirements and over any current investment plans, in an expedient, effective and cost-efficient manner. The Buyback is being undertaken for the following reasons:

  • The Buyback will help the Company to distribute surplus cash to its shareholders holding Equity Shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders
  • The Buyback, which is being implemented through the tender offer route as prescribed under the Buyback Regulations, would involve a reservation of up to 15% of the Buyback Size for small shareholders. The Company believes that this reservation of up to 15% for small shareholders would benefit a large number of public shareholders, who would get classified as "Small Shareholders" as defined in the Buyback Regulations;
  • The Buyback would help in improving financial ratios like earnings per share and return on equity, by reducing the equity base of the Company; and
  • The Buyback gives an option to the Eligible Sellers to either choose to participate in the Buyback and receive cash instead of their Equity Shares which are accepted under the Buyback or choose not to participate in the Buyback and get a resultant increase in their percentage shareholding in the Company post the Buyback, without additional investment as a result of decrease in the paid-up Equity Share Capital.

Buyback Timetable

Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Aarti Drugs Buyback 2024 Buyback record date is Sep 05, 2024. Nucleus Software Buyback 2024 Buyback record date is Sep 03, 2024.

  Aarti Drugs Ltd. Nucleus Software Exports Ltd.
Record Date Sep 05, 2024 Sep 03, 2024
Offer Open Date Sep 11, 2024 Sep 09, 2024
Offer Closure Date Sep 19, 2024 Sep 13, 2024
Last date for receipt of tender forms Sep 19, 2024 Sep 13, 2024
Finalisation of buyback Sep 25, 2024 Sep 20, 2024
Last Date for settlment of bids Sep 26, 2024 Sep 23, 2024
Last Date for extinguishment of shares Oct 08, 2024 Oct 03, 2024

Financial Details and Other Relevent Information

Comparison of Aarti Drugs Buyback 2024 and Nucleus Software Buyback 2024 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Aarti Drugs Ltd. Nucleus Software Exports Ltd.
Financial

Aarti Drugs Ltd. Financial Information (Restated Consolidated)

Aarti Drugs Ltd.'s revenue decreased by -7% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 202231 Mar 2021
Assets2,421.42,207.961,766.01
Revenue2,532.612,718.252,499.962,159.31
Profit After Tax171.59166.36205280.4
Net Worth1,262.071,173.691,016.62
Amount in ₹ Crore

Nucleus Software Exports Ltd. Financial Information (Restated Consolidated)

Nucleus Software Exports Ltd.'s revenue increased by 31% and profit after tax (PAT) rose by 50% between the financial year ending with March 31, 2024 and March 31, 2023.

Period Ended31 Mar 202431 Mar 202331 Mar 2022
Assets1,114.02874.18736.94
Revenue877.35668.52531.85
Profit After Tax191.6127.7940.91
Net Worth750.67583.89466.83
Reserves and Surplus777.44610.66493.6
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.95 500.05 529.89
Jun-2024 538.90 450.20 507.91
May-2024 508.85 453.60 483.92

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 1644.95 1368.95 1497.80
Jun-2024 1512.00 1101.55 1299.43
May-2024 1460.00 1144.00 1315.50
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 563.20 500.00 530.05
Jun-2024 538.95 451.05 508.13
May-2024 508.95 456.00 484.25

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Jul-2024 1645.00 1370.00 1497.60
Jun-2024 1523.40 1104.10 1307.29
May-2024 1474.70 1140.00 1316.19

Comments

Add a public comment...